MIAMI, FL / ACCESSWIRE / April 22, 2016 / Top Nasdaq Stocks is issuing a report on four stocks to watch. COOL, NEOT, EBIO, and ARTX have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the Nasdaq/NYSE subscribe to our newsletter at TopNasdaqStocks.com.
Majesco Entertainment Co. (NASDAQ: COOL) strives to fill its clients' video game needs through the development and publishing of products that are family friendly, available on various platforms, and are appealing to the expanding market of digital entertainment enthusiasts. In addition, over the past 25 years Majesco Entertainment has established working relationships with distributors and retailers, ensuring that all of its products are readily available nationwide. Majesco has experienced gains of 11.85% over the past eight trading days. On April 12th, Majesco's stock fell to a daily low of $0.751, but on April 22nd the equity reached a daily high of $0.84.
Stay Informed and Up To Date On The Hottest NASDAQ Plays. Get Them Here.
Neothetics, Inc. (NASDAQ: NEOT) is a pharmaceutical company currently in the clinical stage that is focused on fulfilling the aesthetic market's need for novel therapeutics. Neothetics is planning to bring its product LIPO-202 into phase II of clinical trials by the third quarter of 2016. LIPO-202 is the industry's first injectable solution that is designed to reduce the size of fat cells in the injection site, without affecting the surrounding tissue. LIPO-202, if approved by the FDA, will be used on non-obese patients as a non-invasive and painless method of reducing belly and chin fat. So far in the month of April, Neothetics' stock price has risen at a rate of 91.38%. This increase is a result of the share price falling as low as $0.58 on April 1st, and reaching as high as $1.11 on April 22nd.
Subscribe Now And Reserve A Spot To Receive Our First Alert Of April. Get Your Free Membership Now.
Eleven Biotherapeutics, Inc. (NASDAQ: EBIO) is a company that has seen its stock climb from a daily low point of $0.31 two weeks ago on April 11th to April 22nd's peak level of $1.12. This surge over the past two weeks translates to a 261.29% increase for the company's stock price. Eleven Biotherapeutics's mission is to treat patients suffering from eye diseases by designing and developing innovative solutions. The company's most advanced preclinical product, EBI-031, is designed to treat vision loss associated with Diabetic Macular Edema (DME), which is among the most common causes of vision loss in the United States.
Enjoy picks like this? Get These Alerts and More on NASDAQ Companies before They Rally, Text the word "NASDAQ" to 77948
Arotech Corp. (NASDAQ: ARTX) is in the business of meeting its clients defense and security needs through the distribution of products that are of the highest quality, and are being purchased by law enforcement and the military. Steven Esses, President and CEO of Arotech, recently spoke with regards to his company being chosen by the U.S. Marines to develop and deliver hybrid mobile power systems, "This contract award is a testament to our team and the performance of our product. We are excited about this opportunity and are optimistic that this award could lead to additional orders in the future." Arotech's stock price has experienced gains of 73.62% since the beginning of April. During the first of the month, the equity's lowest point was $2.35, but on April 22nd the price rose to as high as $4.08.
Stay Informed and Up To Date On The Hottest NASDAQ Plays. Get Them Here.
About TopNasdaqStocks.com
Looking for stock market and business news headlines? How about up to the minute information on mutual funds and ETFs? Don't forget about the top stock picks of 2016. TopNasdaqStocks.com has it all. Make sure to subscribe to our free newsletter and to receive free text message alerts on your phone, text "NASDAQ" to 77948.
Disclosure: The information, opinions and analysis contained in this report are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We do not accept any responsibility or liability for any losses, damages or costs arising from an investor's or other person's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities, nor a recommendation of any security. Past gains are not representative of future gains. Pursuant to an agreement between us and a non affiliate 3rd party we were hired for a period beginning on 3/20/16 and ending on 6/19/16 to publicly disseminate information about (cool) including on the website and other media including facebook and twitter. We are being paid $100,000 (cash) for or were paid "zero" shares of unrestricted or restricted common shares. We own zero shares of (cool), which we purchased in the open market. We plan to sell the "zero" shares of (cool) that we hold during the time the website and/or facebook and twitter information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of (cool) in the open market at any time, including before, during or after the website and information, provide public dissemination of favorable information. Top Nasdaq Stocks has not been compensated nor does it expect to receive any compensation for distribution of its opinions and publicly available information regarding NEOT, EBIO, or ARTX in this investment opinion article at this time. The opinions contained herein contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. When used herein, the words "anticipate," "intend," "estimate," "believe," "expect," "plans," "should," "potential," "forecast," and variations of such words and similar expressions are intended to identify forward-looking statements. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. A company's actual results could differ materially from those described in any forward-looking statements contained herein. Top Nasdaq Stocks is not a licensed broker, broker dealer, market maker, investment advisor, analyst or underwriter. We recommend that you use the information found herein as an initial starting point for conducting your own research in order to determine your own personal opinion of the companies discussed herein before deciding whether or not to invest. You should seek such investment, tax, financial, accounting or legal advice appropriate for your particular circumstances. Information about many publicly traded companies and other investor resources can be found at www.sec.gov. Investing in securities is speculative and carries risk. Please visit http://topnasdaqstocks.com/index.php/disclaimer/ website for a more detailed discussion of risks and disclosures.
Contact:
Top Nasdaq Stocks
news@topnasdaqstocks.com
SOURCE: Top Nasdaq Stocks
ReleaseID: 439127
